Merck expects Keytruda to face HHS price setting in 2026
Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...
Merck expects cancer therapy Keytruda to be part of government price setting in 2026
(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...
3 Magnificent S&P 500 Dividend Stocks Down 36% to 64% to Buy and Hold Forever
The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
MedPage Today1d
BRCA1 Contribution to Prostate Cancer Called Into Question
Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
MRK Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Merck & Co., Inc. Securities Class Action
SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Maybe The Ultimate Laggard’
We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...
Merck & Co., Inc. (MRK): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
A little-known Chinese company made a drug that beat the world’s biggest selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Merck & Co. Inc. stock outperforms competitors on strong trading day
Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...
Merck Gets Speedy FDA Review of Keytruda in Certain Head, Neck Cancers
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.